Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: A prospective multicentre study

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 899-907

  Girón González, José A ^a   Brun, Francisco ^a   Terrón, Alberto ^b   Vergara, Antonio ^c   Arizcorreta, Ana ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL DE JEREZ   (Spain)

^c HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL READMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 34848825084     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Benhamou Y, Bochet M, di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058.
2. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-498.
3. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus-infected patients. Gut 2003; 52:1035-1040.
4. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
5. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744-749.
6. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-830.
7. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183:1112-1115.
8. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584-1589.
9. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789.
10. Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57.
11. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV coinfection. AIDS 2004; 18:1-12.
12. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33:846-852.
13. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39:2-16.
14. Gines P, Cabrera J, Guevara M, et al. Documento de consenso sobre el tratamiento de la ascitis, la hiponatremia dilucional y el síndrome hepatorenal en la cirrosis hepática. [Consensus document on the treatment of ascites, dilutional hyponatremia and hepatorenal syndrome in liver cirrhosis]. Gastroenterología y Hepatología 2004; 27:535-544. Spanish.
15. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32:142-153.
16. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35:716-721.
17. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003;188:1412-1420.
18. + cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors. Eur J Clin Microbiol Infect Dis 2000; 19:852-858.
19. Graham CS, Baden LR, Yu E, et al. Influence of human immunodefiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33:562-569
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520
21. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21:1023-1032
22. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
23. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
24. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31:468-475
25. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 2001; 49:682-685.
26. Bernard B, Granger JD, Nguyen Khac E, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29:1655-1661.
27. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
28. Bonacini M, Louie S, Bzowej N, Rock Wohl A. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2045.
29. Sobesky R, Mathurin P, Charlotte F, et al. Modelling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378-386.
30. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.